Cantargia: New Biomarker Results in Pancreatic Cancer - Redeye
Bildkälla: Stockfoto

Cantargia: New Biomarker Results in Pancreatic Cancer - Redeye

Redeye believes the new biomarker results with nadunolimab to be presented at the AACR Annual Meeting 2023 validate the scientific understanding of nadunolimab.

Börsvärldens nyhetsbrev